Dupilumab

Generic Name
Dupilumab
Brand Names
Dupixent
Drug Type
Biotech
Chemical Formula
-
CAS Number
1190264-60-8
Unique Ingredient Identifier
420K487FSG
Background

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...

Indication

In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...

Associated Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
Associated Therapies
Add-on therapy, Maintenance therapy
Clinical Trials
Related News

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

First Posted Date
2015-08-19
Last Posted Date
2019-10-01
Lead Sponsor
Sanofi
Target Recruit Count
210
Registration Number
NCT02528214
Locations
🇪🇸

Investigational Site Number 724014, Barcelona, Spain

🇪🇸

Investigational Site Number 724006, Pozuelo De Alarcón, Spain

🇦🇷

Investigational Site Number 032001, Caba, Argentina

and more 77 locations

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

First Posted Date
2015-04-13
Last Posted Date
2018-10-23
Lead Sponsor
Sanofi
Target Recruit Count
1902
Registration Number
NCT02414854
Locations
🇯🇵

Investigational Site Number 392168, Uozu-Shi, Japan

🇺🇸

Investigational Site Number 840011, Los Angeles, California, United States

🇺🇸

Investigational Site Number 840021, San Jose, California, United States

and more 386 locations

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Dupilumab
First Posted Date
2015-04-03
Last Posted Date
2020-11-27
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
78
Registration Number
NCT02407756

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
Drug: Dupilumab
First Posted Date
2015-03-20
Last Posted Date
2020-03-11
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
422
Registration Number
NCT02395133

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Phase 2
Completed
Conditions
Eosinophilic Esophagitis
Interventions
Drug: Dupilumab
Drug: Placebo
First Posted Date
2015-03-04
Last Posted Date
2020-02-28
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
47
Registration Number
NCT02379052

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

First Posted Date
2014-10-29
Last Posted Date
2020-06-02
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
708
Registration Number
NCT02277769

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

First Posted Date
2014-10-29
Last Posted Date
2017-11-21
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
671
Registration Number
NCT02277743

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

First Posted Date
2014-10-09
Last Posted Date
2017-10-17
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
740
Registration Number
NCT02260986

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
Drug: Dupilumab
First Posted Date
2014-08-07
Last Posted Date
2020-05-07
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
194
Registration Number
NCT02210780

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Dupilumab
First Posted Date
2014-05-08
Last Posted Date
2022-03-28
Lead Sponsor
Sanofi
Target Recruit Count
2282
Registration Number
NCT02134028
Locations
🇺🇸

Investigational Site Number 840402, Tucson, Arizona, United States

🇺🇸

Investigational Site Number 840045, Long Beach, California, United States

🇺🇸

Investigational Site Number 840044, Newport Beach, California, United States

and more 362 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy